Rhein exhibits antitumorigenic effects by interfering with the interaction between prolyl isomerase Pin1 and c-Jun

Cho,Jin Hyoung; Chae,Jung-Il; Shim,Jung-Hyun

doi:10.3892/or.2017.5434

Rhein exhibits antitumorigenic effects by interfering with the interaction between prolyl isomerase Pin1 and c-Jun

Authors:
- Jin Hyoung Cho
- Jung-Il Chae
- Jung-Hyun Shim
View Affiliations

Affiliations: Department of Dental Pharmacology, School of Dentistry and Institute of Oral Bioscience, BK21 Plus, Chonbuk National University, Jeonju-si, Jeollabuk-do 54896, Republic of Korea, Department of Pharmacy, College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Jeonnam 58554, Republic of Korea
Published online on: February 7, 2017 https://doi.org/10.3892/or.2017.5434
Pages: 1865-1872

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Pin1 protein (or peptidyl-prolyl cis/trans isomerase) specifically catalyzes the cis/trans isomerization of phosphorylated serine/threonine-proline (Ser/Thr-Pro) bonds and plays an important role in many cellular events through the effects of conformational change in the function of c-Jun, its biological substrate. Pin1 expression is involved in essential cellular pathways that mediate cell proliferation, cell cycle progression, tumorigenesis and apoptosis by altering their stability and function, and it is overexpressed in various types of tumors. Pin1 phosphorylation has been regarded as a marker of Pin1 isomerase activity, and the phosphorylation of Ser/Thr-Pro on protein substrates is prerequisite for its binding activity with Pin1 and subsequent isomerization. Since phosphorylation of proteins on Ser/Thr-Pro is a key regulatory mechanism in the control of cell proliferation and transformation, Pin1 has become an attractive molecule in cancer research. Many inhibitors of Pin1 have been discovered, including several classes of both designed inhibitors and natural products. Anthraquinone compounds possess antitumor properties and have therefore been applied in human and veterinary therapeutics as active substances in medicinal products. Among the anthraquinones, rhein (4,5-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid) is a monomeric anthraquinone derivative found mainly in plants in the Polygonaceae family, such as rhubarb and Polygonum cuspidatum. Recent studies have shown that rhein has numerous pharmacological activities, including antitumor effects. Here, we demonstrated the antitumorigenic effect of rhein using cell proliferation assay, anchorage-independent cell transformation, pull-down assay, luciferase promoter activity, fluorescence-activated cell sorting and western blot analysis. The rhein/Pin1 association was found to play a regulatory role in cell proliferation and neoplastic cell transformation and the binding of phosphorylated c-Jun (Ser73) with Pin1 was markedly decreased and inhibited activator protein 1 or NF-κB reporter activity by rhein. Overall, our findings and the accompanying biochemical data demonstrated the antitumorigenic effect of rhein through its interference in Pin1/c-Jun interaction and suggest the possible use of rhein in suppressing the tumor-promoting effects of Pin1. Therefore, rhein may have practical implications for cancer prevention or therapy.

View Figures

View References

1	Li Y, Xu Y, Lei B, Wang W, Ge X and Li J: Rhein induces apoptosis of human gastric cancer SGC-7901 cells via an intrinsic mitochondrial pathway. Braz J Med Biol Res. 45:1052–1059. 2012. View Article : Google Scholar : PubMed/NCBI
2	Tsang SW and Bian ZX: Anti-fibrotic and anti-tumorigenic effects of rhein, a natural anthraquinone derivative, in mammalian stellate and carcinoma cells. Phytother Res. 29:407–414. 2015. View Article : Google Scholar : PubMed/NCBI
3	Tsang SW, Zhang H, Lin C, Xiao H, Wong M, Shang H, Yang ZJ, Lu A, Yung KK and Bian Z: Rhein, a natural anthraquinone derivative, attenuates the activation of pancreatic stellate cells and ameliorates pancreatic fibrosis in mice with experimental chronic pancreatitis. PLoS One. 8:e822012013. View Article : Google Scholar : PubMed/NCBI
4	Lai WW, Yang JS, Lai KC, Kuo CL, Hsu CK, Wang CK, Chang CY, Lin JJ, Tang NY, Chen PY, et al: Rhein induced apoptosis through the endoplasmic reticulum stress, caspase- and mitochondria-dependent pathways in SCC-4 human tongue squamous cancer cells. In Vivo. 23:309–316. 2009.PubMed/NCBI
5	Chen YY, Chiang SY, Lin JG, Yang JS, Ma YS, Liao CL, Lai TY, Tang NY and Chung JG: Emodin, aloe-emodin and rhein induced DNA damage and inhibited DNA repair gene expression in SCC-4 human tongue cancer cells. Anticancer Res. 30:945–951. 2010.PubMed/NCBI
6	Chen YY, Chiang SY, Lin JG, Ma YS, Liao CL, Weng SW, Lai TY and Chung JG: Emodin, aloe-emodin and rhein inhibit migration and invasion in human tongue cancer SCC-4 cells through the inhibition of gene expression of matrix metalloproteinase-9. Int J Oncol. 36:1113–1120. 2010.PubMed/NCBI
7	Aviello G, Rowland I, Gill CI, Acquaviva AM, Capasso F, McCann M, Capasso R, Izzo AA and Borrelli F: Anti-proliferative effect of rhein, an anthraquinone isolated from Cassia species, on Caco-2 human adenocarcinoma cells. J Cell Mol Med. 14:2006–2014. 2010. View Article : Google Scholar : PubMed/NCBI
8	Lin YJ and Zhen YS: Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice. Anticancer Drugs. 20:65–72. 2009. View Article : Google Scholar : PubMed/NCBI
9	Shi P, Huang Z and Chen G: Rhein induces apoptosis and cell cycle arrest in human hepatocellular carcinoma BEL-7402 cells. Am J Chin Med. 36:805–813. 2008. View Article : Google Scholar : PubMed/NCBI
10	Ip SW, Weng YS, Lin SY, Mei-Dueyang Tang NY, Su CC and Chung JG: The role of Ca+2 on rhein-induced apoptosis in human cervical cancer Ca Ski cells. Anticancer Res. 27:379–389. 2007.PubMed/NCBI
11	Shrimali D, Shanmugam MK, Kumar AP, Zhang J, Tan BK, Ahn KS and Sethi G: Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett. 341:139–149. 2013. View Article : Google Scholar : PubMed/NCBI
12	Domagala F, Martin G, Bogdanowicz P, Ficheux H and Pujol JP: Inhibition of interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1: Potential mechanism for Diacerein effects in osteoarthritis. Biorheology. 43:577–587. 2006.PubMed/NCBI
13	Wulf GM, Liou YC, Ryo A, Lee SW and Lu KP: Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem. 277:47976–47979. 2002. View Article : Google Scholar : PubMed/NCBI
14	Zhou XZ, Kops O, Werner A, Lu PJ, Shen M, Stoller G, Küllertz G, Stark M, Fischer G and Lu KP: Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell. 6:873–883. 2000. View Article : Google Scholar : PubMed/NCBI
15	Chen HI and Sudol M: The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc Natl Acad Sci USA. 92:7819–7823. 1995. View Article : Google Scholar : PubMed/NCBI
16	Lu PJ, Zhou XZ, Shen M and Lu KP: Function of WW domains as phosphoserine- or phosphothreonine-binding modules. Science. 283:1325–1328. 1999. View Article : Google Scholar : PubMed/NCBI
17	Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, Rahfeld JU, Xu J, Kuang J, Kirschner MW, Fischer G, et al: Sequence-specific and phosphorylation-dependent proline isomerization: A potential mitotic regulatory mechanism. Science. 278:1957–1960. 1997. View Article : Google Scholar : PubMed/NCBI
18	Lu KP and Zhou XZ: The prolyl isomerase PIN1: A pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol. 8:904–916. 2007. View Article : Google Scholar : PubMed/NCBI
19	Yeh ES and Means AR: PIN1, the cell cycle and cancer. Nat Rev Cancer. 7:381–388. 2007. View Article : Google Scholar : PubMed/NCBI
20	Lu KP: Pinning down cell signaling, cancer and Alzheimer's disease. Trends Biochem Sci. 29:200–209. 2004. View Article : Google Scholar : PubMed/NCBI
21	Lu KP, Liou YC and Zhou XZ: Pinning down proline-directed phosphorylation signaling. Trends Cell Biol. 12:164–172. 2002. View Article : Google Scholar : PubMed/NCBI
22	Wulf G, Finn G, Suizu F and Lu KP: Phosphorylation-specific prolyl isomerization: Is there an underlying theme? Nat Cell Biol. 7:435–441. 2005. View Article : Google Scholar : PubMed/NCBI
23	Ryo A, Nakamura M, Wulf G, Liou YC and Lu KP: Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol. 3:793–801. 2001. View Article : Google Scholar : PubMed/NCBI
24	Dominguez-Sola D and Dalla-Favera R: PINning down the c-Myc oncoprotein. Nat Cell Biol. 6:288–289. 2004. View Article : Google Scholar : PubMed/NCBI
25	Sears RC: The life cycle of C-myc: From synthesis to degradation. Cell Cycle. 3:1133–1137. 2004. View Article : Google Scholar : PubMed/NCBI
26	Bao L, Kimzey A, Sauter G, Sowadski JM, Lu KP and Wang DG: Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol. 164:1727–1737. 2004. View Article : Google Scholar : PubMed/NCBI
27	Ryo A, Liou YC, Wulf G, Nakamura M, Lee SW and Lu KP: PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol. 22:5281–5295. 2002. View Article : Google Scholar : PubMed/NCBI
28	Lu KP, Hanes SD and Hunter T: A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature. 380:544–547. 1996. View Article : Google Scholar : PubMed/NCBI
29	Chang CY, Chan HL, Lin HY, Way TD, Kao MC, Song MZ, Lin YJ and Lin CW: Rhein induces apoptosis in human breast cancer cells. Evid Based Complement Alternat Med. 2012:9525042012. View Article : Google Scholar : PubMed/NCBI
30	Wulf G, Garg P, Liou YC, Iglehart D and Lu KP: Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis. EMBO J. 23:3397–3407. 2004. View Article : Google Scholar : PubMed/NCBI
31	Fujimori F, Takahashi K, Uchida C and Uchida T: Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest. Biochem Biophys Res Commun. 265:658–663. 1999. View Article : Google Scholar : PubMed/NCBI
32	Cho YS, Park SY, Kim DJ, Lee SH, Woo KM, Lee KA, Lee YJ, Cho YY and Shim JH: TPA-induced cell transformation provokes a complex formation between Pin1 and 90 kDa ribosomal protein S6 kinase 2. Mol Cell Biochem. 367:85–92. 2012. View Article : Google Scholar : PubMed/NCBI
33	Urusova DV, Shim JH, Kim DJ, Jung SK, Zykova TA, Carper A, Bode AM and Dong Z: Epigallocatechin-gallate suppresses tumorigenesis by directly targeting Pin1. Cancer Prev Res (Phila). 4:1366–1377. 2011. View Article : Google Scholar : PubMed/NCBI
34	Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G, Rottapel R, Yamaoka S and Lu KP: Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell. 12:1413–1426. 2003. View Article : Google Scholar : PubMed/NCBI
35	Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V and Lu KP: Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 20:3459–3472. 2001. View Article : Google Scholar : PubMed/NCBI
36	Martin G, Bogdanowicz P, Domagala F, Ficheux H and Pujol JP: Rhein inhibits interleukin-1 beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappa B and AP-1 in chondrocytes cultured in hypoxia: A potential mechanism for its disease-modifying effect in osteoarthritis. Inflammation. 27:233–246. 2003. View Article : Google Scholar : PubMed/NCBI
37	Legendre F, Bogdanowicz P, Martin G, Domagala F, Leclercq S, Pujol JP and Ficheux H: Rhein, a diacerhein-derived metabolite, modulates the expression of matrix degrading enzymes and the cell proliferation of articular chondrocytes by inhibiting ERK and JNK-AP-1 dependent pathways. Clin Exp Rheumatol. 25:546–555. 2007.PubMed/NCBI
38	Lin FC, Lee YC, Goan YG, Tsai CH, Yao YC, Cheng HC, Lai WW, Wang YC, Sheu BS and Lu PJ: Pin1 positively affects tumorigenesis of esophageal squamous cell carcinoma and correlates with poor survival of patients. J Biomed Sci. 21:752014. View Article : Google Scholar : PubMed/NCBI
39	Liou YC, Zhou XZ and Lu KP: Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci. 36:501–514. 2011. View Article : Google Scholar : PubMed/NCBI
40	Lu KP: Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics. Cancer Cell. 4:175–180. 2003. View Article : Google Scholar : PubMed/NCBI
41	Chien SC, Wu YC, Chen ZW and Yang WC: Naturally occurring anthraquinones: Chemistry and therapeutic potential in autoimmune diabetes. Evid Based Complement Alternat Med. 2015:3573572015. View Article : Google Scholar : PubMed/NCBI
42	Roman-Blas JA and Jimenez SA: NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage. 14:839–848. 2006. View Article : Google Scholar : PubMed/NCBI
43	Zhou YX, Xia W, Yue W, Peng C, Rahman K and Zhang H: Rhein: A review of pharmacological activities. Evid Based Complement Alternat Med. 2015:5781072015. View Article : Google Scholar : PubMed/NCBI
44	Bayer E, Goettsch S, Mueller JW, Griewel B, Guiberman E, Mayr LM and Bayer P: Structural analysis of the mitotic regulator hPin1 in solution: Insights into domain architecture and substrate binding. J Biol Chem. 278:26183–26193. 2003. View Article : Google Scholar : PubMed/NCBI